Katherine A Hirchak1,2, Sean M Murphy2,3. 1. Department of Human Development, Prevention Science Program, Washington State University, Pullman, Washington. 2. Health Sciences Spokane, Washington State University, Spokane, Washington. 3. Department of Health Policy and Administration, Spokane, Washington.
Abstract
BACKGROUND: Opioid misuse is a large public health problem in the United States. Residents of rural areas and American Indian (AI) reservation/trust lands represent traditionally underserved populations with regard to substance-use disorder therapy. PURPOSE: Assess differences in the number of opioid agonist therapy (OAT) facilities and physicians with Drug Addiction Treatment Act (DATA) waivers for rural versus urban, and AI reservation/trust land versus non-AI reservation/trust land areas in Washington State. METHODS: The unit of analysis was the ZIP code. The dependent variables were the number of OAT facilities and DATA-waivered physicians in a region per 10,000 residents aged 18-64 in a ZIP code. A region was defined as a ZIP code and its contiguous ZIP codes. The independent variables were binary measures of whether a ZIP code was classified as rural versus urban, or AI reservation/trust land versus non-AI reservation/trust land. Zero-inflated negative binomial regressions with robust standard errors were estimated. RESULTS: The number of OAT clinics in a region per 10,000 ZIP-code residents was significantly lower in rural versus urban areas (P = .002). This did not differ significantly between AI reservation/trust land and non-AI reservation/trust land areas (P = .79). DATA-waivered physicians in a region per 10,000 ZIP-code residents was not significantly different between rural and urban (P = .08), or AI reservation/trust land versus non-AI reservation/trust land areas (P = .21). CONCLUSIONS: It appears that the potential for Washington State residents of rural and AI reservation areas to receive OAT is similar to that of residents outside of those areas; however, difficulties in accessing therapy may remain, highlighting the importance of expanding health care insurance and providing support for DATA-waivered physicians.
BACKGROUND: Opioid misuse is a large public health problem in the United States. Residents of rural areas and American Indian (AI) reservation/trust lands represent traditionally underserved populations with regard to substance-use disorder therapy. PURPOSE: Assess differences in the number of opioid agonist therapy (OAT) facilities and physicians with Drug Addiction Treatment Act (DATA) waivers for rural versus urban, and AI reservation/trust land versus non-AI reservation/trust land areas in Washington State. METHODS: The unit of analysis was the ZIP code. The dependent variables were the number of OAT facilities and DATA-waivered physicians in a region per 10,000 residents aged 18-64 in a ZIP code. A region was defined as a ZIP code and its contiguous ZIP codes. The independent variables were binary measures of whether a ZIP code was classified as rural versus urban, or AI reservation/trust land versus non-AI reservation/trust land. Zero-inflated negative binomial regressions with robust standard errors were estimated. RESULTS: The number of OAT clinics in a region per 10,000 ZIP-code residents was significantly lower in rural versus urban areas (P = .002). This did not differ significantly between AI reservation/trust land and non-AI reservation/trust land areas (P = .79). DATA-waivered physicians in a region per 10,000 ZIP-code residents was not significantly different between rural and urban (P = .08), or AI reservation/trust land versus non-AI reservation/trust land areas (P = .21). CONCLUSIONS: It appears that the potential for Washington State residents of rural and AI reservation areas to receive OAT is similar to that of residents outside of those areas; however, difficulties in accessing therapy may remain, highlighting the importance of expanding health care insurance and providing support for DATA-waivered physicians.
Authors: Andrew W Dick; Rosalie L Pacula; Adam J Gordon; Mark Sorbero; Rachel M Burns; Douglas Leslie; Bradley D Stein Journal: Health Aff (Millwood) Date: 2015-06 Impact factor: 6.301
Authors: Bradley D Stein; Adam J Gordon; Andrew W Dick; Rachel M Burns; Rosalie Liccardo Pacula; Carrie M Farmer; Douglas L Leslie; Mark Sorbero Journal: J Subst Abuse Treat Date: 2014-08-02
Authors: Kelly E Dunn; Frederick S Barrett; Claudia Yepez-Laubach; Andrew C Meyer; Bryce J Hruska; Kathy Petrush; Suzan Berman; Stacey C Sigmon; Michael Fingerhood; George E Bigelow Journal: J Subst Abuse Treat Date: 2016-12
Authors: Valerie S Harder; Andrea C Villanti; Sarah H Heil; M Lindsey Smith; Diann E Gaalema; Marjorie C Meyer; Nathaniel H Schafrick; Stacey C Sigmon Journal: Prev Med Date: 2021-08-16 Impact factor: 4.018
Authors: Elizabeth C Saunders; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch Journal: Prev Med Date: 2021-09-07 Impact factor: 4.018
Authors: Paul J Joudrey; Nicholas Chadi; Payel Roy; Kenneth L Morford; Paxton Bach; Simeon Kimmel; Emily A Wang; Susan L Calcaterra Journal: Drug Alcohol Depend Date: 2020-03-27 Impact factor: 4.492
Authors: Deborah W Garnick; Constance M Horgan; Andrea Acevedo; Margaret T Lee; Lee Panas; Grant A Ritter; Kevin Campbell Journal: J Rural Health Date: 2019-05-15 Impact factor: 4.333
Authors: Sean M Murphy; Philip J Jeng; Kathryn E McCollister; Jared A Leff; Ali Jalali; Matisyahu Shulman; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman Journal: Addiction Date: 2021-05-21 Impact factor: 6.526
Authors: A Taylor Kelley; Marcela C Smid; Jacob D Baylis; Elizabeth Charron; Amy E Binns-Calvey; Shayla Archer; Saul J Weiner; Lori Jo Begaye; Gerald Cochran Journal: Addict Sci Clin Pract Date: 2021-06-25